Fuchs Endothelial Corneal Dystrophy (FECD): Competitive Landscape

Fuchs Endothelial Corneal Dystrophy (FECD): Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in FECD therapeutics.

• More than 133,000,000 total prevalent cases of FECD are expected in 2024 in the 16 countries covered in GlobalData’s epidemiology forecast for FECD.
• Currently there are no FDA approved therapies for FECD. The most recent guideline for FECD was developed by the American Academy of Ophthalmology.
• The pipeline for FECD mainly consists of enzyme inhibitors Rho kinase 2 inhibitor and mTOR (mammalian target of rapamycin) inhibitor.
• Around 59% of worldwide trials addressing FECD were conducted in the North America region, followed by Europe with 26.47% of trials and Asia-Pacific with 14.7% of the total trials.
• In deals involving companies developing FECD assets that occurred during past 10 years, partnership emerged as the dominant deal type in Europe and Asia-Pacific.

Scope

GlobalData’s FECD: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the FECD market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global FECD market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.